Different Statin Effects of ST-elevation Versus Non-ST-Elevation Acute Myocardial Infarction After Stent Implantation
Yong Hoon Kim1, Ae-Young Her1, Myung Ho Jeong2
1Division of Cardiology, Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Republic of Korea.
Insights
Statin therapy significantly reduced major adverse cardiac events and death in acute myocardial infarction patients. However, statin effectiveness was greater in ST-segment elevation myocardial infarction (STEMI) than non-STEMI (NSTEMI) patients after stent implantation.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- Intensive statin therapy is crucial for reducing cardiovascular events in acute coronary syndrome (ACS).
- Long-term data on statin therapy's impact in ST-segment elevation myocardial infarction (STEMI) versus non-STEMI (NSTEMI) post-drug-eluting stent (DES) is limited.
- Understanding these differences is vital for optimizing patient management and outcomes.
Purpose of the Study:
- To compare the 2-year clinical outcomes of statin therapy between STEMI and NSTEMI patients.
- To evaluate the effectiveness of statins in reducing major adverse cardiac events (MACE) in different acute myocardial infarction (AMI) subgroups.
- To assess the long-term impact of statin use versus non-use in these patient populations.
Main Methods:
- A retrospective analysis of 30,616 Korean patients with AMI.
- Patients were categorized into four groups: STEMI statin users (Group A), STEMI non-users (Group B), NSTEMI statin users (Group C), and NSTEMI non-users (Group D).
- The primary endpoint was MACE (all-cause death, recurrent myocardial infarction, repeat revascularization) over a 2-year follow-up.
Main Results:
- After adjustment, NSTEMI statin users (Group C) had significantly higher risks of MACE, all-cause death, and target vessel revascularization (TVR) compared to STEMI statin users (Group A).
- Statin non-users (Groups B and D) exhibited significantly higher cumulative risks of MACE, all-cause death, and cardiac death compared to statin users (Groups A and C).
- These findings highlight the substantial benefit of statin therapy across AMI types, with differential effects observed between STEMI and NSTEMI.
Conclusions:
- Statin therapy demonstrates superior effectiveness in mitigating MACE, all-cause death, and TVR in STEMI patients compared to NSTEMI patients.
- The study confirms the significant benefit of statin therapy in reducing adverse cardiac events in Korean patients with AMI post-DES implantation.
- These results underscore the importance of consistent statin use for improving long-term outcomes in ACS patients, particularly differentiating between STEMI and NSTEMI.
Background:
Intensive statin therapy reduces cardiovascular events in acute coronary syndrome. The data concerning the long-term clinical impacts of statin therapy between ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) after drug-eluting stent implantation are limited. We compared the 2-year clinical outcomes between these 2 groups after statin therapy.
Materials And Methods:
A total of 30,616 Korean patients with acute myocardial infarction (AMI) were enrolled. Among them, 13,686 patients were classified as group A (STEMI statin user), 3,824 patients were as group B (STEMI statin nonuser), 10,398 patients were as group C (NSTEMI statin user), and 2,708 patients were as group D (NSTEMI statin nonuser). The major clinical endpoint was the occurrence of major adverse cardiac events (MACE) defined as all-cause death, recurrent myocardial infarction (re-MI), and any repeat revascularization during a 2-year follow-up period.
Results:
After adjustment, the cumulative risks of MACE (adjusted hazard ratio [aHR] = 1.112 [1.002-1.235]; P = 0.047), all-cause death (aHR = 1.271 [1.054-1.532]; P = 0.012), and target vessel revascularization (TVR, aHR = 1.262 [1.049-1.518]; P = 0.014) in group C were significantly higher than group A. The cumulative risks of MACE, all-cause death, and cardiac death of the statin nonuser group (groups B and D) were significantly higher compared with statin user group (groups A and C).
Conclusions:
Statin therapy was more effective in reducing the cumulative risks of MACE, all-cause death, and TVR in the STEMI group than NSTEMI group in Korean patients with AMI after successful drug-eluting stent implantation.
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:27Coronary Artery Disease V: Interprofessional Care